The SeroSelectTB test will be evaluated at 21 primary healthcare units Moshi Urban, Moshi Rural and Hai Districts in Kilimanjaro Region, Tanzania. TB suspects self-reporting to the study sites will be randomised in two arms: standard-of-care or SeroSelectTB. In Tanzania, 2829 TB suspects will be enrolled in each study arm.

 

This section will be updated as the clinical trial proceeds.